Hematogenix's Mm Mrd Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's Zenbexus™, the First Approved CELMoD Therapy for Multiple Myeloma PR Newswire (Press Release) 7d
Zenbexus Granted Accelerated Approval in Relapsed or Refractory Multiple Myeloma Hematology Advisor 15:35 Mon, 17 Aug
Hematogenix's Proprietary MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's ZENBEXUS™, the First Approved CELMoD Therapy for Multiple Myeloma PRWeb (Press Release) 23:30 Fri, 14 Aug
BMS Targets Community Setting With Zenbexus, Its First Approved CELMoD Scrip Pharma Intelligence 21:34 Fri, 14 Aug
Protein degrader approval offers hope to relapsed multiple myeloma patients Chemistry World Magazine 1d Chemistry Pharma Zenbexus All sources
Is the reported $400 billion AstraZeneca-Bristol Myers Squibb megamerger a slam dunk -- or a disaster waiting to happen? The Motley Fool 03:08 Fri, 14 Aug AstraZeneca Pharma All sources
Bristol Myers Squibb to build new plant in Houston Pharmaceutical Processing World 19:47 Thu, 13 Aug Pharma All sources
J&J’s Imaavy secures expanded US approval in rare blood disorder Pharmaceutical Technology 13h Johnson and Johnson
